卡培他滨联合DC/CIK维持治疗老年晚期转移性结直肠癌的疗效观察  

Effect of Maintenance Therapy with the Combinations of Capecitabine and Dendritic Cells: Cytokine- induced Killer Cells in Elderly Patients with Advanced Metastatic Colorectal Cancer

作　　者：王宇[1] 袁彩君[2] 刘晓梅[2] 

机构地区：[1]辽宁医学院研究生学院 [2]辽宁医学院附属第一医院肿瘤科,辽宁锦州121000

出　　处：《辽宁医学院学报》2015年第2期66-69,F0003,共5页Journal of Liaoning Medical University (LNMU) Bimonthly

摘　　要：目的研究卡培他滨联合DC/CIK(Dendritic cells:cytokine-induced killer cells)和单药卡培他滨维持治疗老年晚期转移性结直肠癌(metastatic colorectal cancer,m CRC)的疗效及安全性。方法收集自2009年2月1日至2012年2月1日在辽宁医学院附属第一医院完成一线化疗后达到疾病控制(CR+PR+SD)的老年晚期转移性结直肠癌患者98例,按患者意愿结合家庭经济情况分为实验组和对照组。实验组40例,给予卡培他滨和DC/CIK维持治疗,对照组58例,予卡培他滨单药维持治疗。评价两组患者的无进展生存时间(Progression-free survival,PFS)、总生存期(overall survival,OS)及不良反应。结果两组的的中位无进展生存时间分别为10.0月(95%CI:7.676-12.324)、8.4月(95%CI:6.783-10.017),差异有统计学意义(P=0.000);中位总生存期分别为38月(95%CI:33.351-42.649)、28.5月(95%CI:25.235-31.765),差异有统计学意义(P=0.000)。两组的主要不良反应为消化道反应、手足综合征、口腔炎等。联合组输注DC/CIK过程中皮疹1例,呼吸困难1例,发热2例,乏力5例。结论卡培他滨联合DC/CIK维持治疗老年m CRC是安全有效的,可以进一步扩大样本深入研究。Objective To investigate the efficacy and safety of maintenance therapy by using a combination of dentric cells（ DC） /cytokine induced killer cells（ CIK cells） and capecitabine in elderly patients with advanced metastatic colorectal cancer.Methods From September 1st,2009 to September 1st,2012,98 elderly patients with advanced metastatic colorectal cancer in the first affiliated hospital of Liaoning Medical University were selected for the study and their data was collected. The patients were assigned into two groups,the treatment group and the control group,according to their personal willingness and financial capability after they had achieved clinical response（ CR ＋ PR ＋ SD） from the first- 1ine chemotherapy. The treatment group（ 40 cases） was treated with the maintenance therapy using a combination of capecitabine and DC / CIK cells,while the control group（ 58 cases） was given capecitabine alone. The progression- free survival（ PFS）,the overall survival time and the adverse drug reaction of the two groups were observed and evaluated. Results The median progression- free survival time was 10. 0 months and 8. 4 months（ P = 0. 000） for the treatment group and the controlled group,respectively. The differences was statistically significant（ P = 0. 000）. The median overall survival time of patients in the treatment group and the controlled group was 38. 0 months and 28. 5 months（ P = 0. 000）. The result was statistically significant. The major side effects in both groups were the digestive tract reaction,the hand- foot syndrome and the stomatitis. Side effects in the treatment group included： rashes（ 1 case）,dyspnea（ 1 case）,fever（ 2 cases） and acratia（ 5 cases）during DC / CIK infusion period. Conclusion The maintenance treatment of capecitabine combined with DC / CIK cells is a safe,effective and generally well- tolerated method in treating the elderly patients with advanced metastatic colorectal cancer,worthy of enlarging the sample for further research.

关 键 词：结直肠肿瘤 维持治疗 卡培他滨 老年人 DC-CIK细胞 

分 类 号：R735[医药卫生—肿瘤]